DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases

DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases is a phase 3, randomised interventional study registered as NCT06555003 by Tehran University of Medical Sciences, with a registry enrolment figure of 116 participants, started 2025-01-20 and due to reach its primary completion in 2027-10. Interventions recorded: Drug-Eluting Embolic Bead; Chemotherapy drug. Conditions listed: Liver Neoplasm; Colorectal Cancer Metastatic. Primary outcome: Conversion to resectability: The proportion of patients who were initially deemed unresectable but, after undergoing specific intervention (Based on study arm) are reassessed for tumor shrinkage and found to be candidates for surgical resection.. Colorectal eligibility wording from the registry: "* unresectable/borderline resectable colorectal cancer liver metastases, chemotherapy-naïve for metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less adequate hematologic, hepatic, and renal function ( absolute neutrophil count ≥ 1". Sites: Iran. No results are recorded here; the registry entry is the source.